A peer-reviewed New England Journal of Medicine case report described complete regression of chemotherapy-resistant metastatic hepatoblastoma in a three-year-old treated with autologous GPC3-directed CAR T cells coexpressing interleukin-15 and interleukin-21. The child received two…
A Nature paper published online September 9 reports that TRI-611 is an oral, brain-penetrant cereblon molecular-glue degrader that binds a distal ALK surface and eliminates wild-type and kinase-inhibitor-resistant ALK fusion proteins. The compound drove…
A peer-reviewed Blood study used CRISPR/Cas9 to delete the endogenous Notch1 PEST domain in CD19-4-1BBζ CAR T cells, extending native Notch1 signaling without constitutive overexpression. Edited cells expanded more strongly after activation, increased in-vitro…
Novartis discontinued VHB937, also known as lifonebart, in amyotrophic lateral sclerosis after the 251-participant Phase II ASTRALS study missed its primary and secondary endpoints. The company-issued community update was published August 25, 2026 and…
Chengdu-based Beyang Therapeutics closed an oversubscribed Series A of nearly $30 million, co-led by Legend Capital and Shanghai Healthcare Capital. Proceeds will support the ExCEED AI/molecular-design platform, clinical and preclinical programs and international development….
Boulevard Bio emerged from stealth with approximately $65 million in aggregate equity and convertible-note financing from Deerfield and affiliates. Its precision-immunology pipeline includes BLVD101, a dual BAFF/APRIL antibody with interim single-dose healthy-volunteer pharmacology supporting…
Bridge to Life completed $110 million of Series C equity and debt financing to expand the U.S. launch of its VitaSmart hypothermic oxygenated perfusion system, advance an organ-viability assessment tool, scale global operations and…
A peer-reviewed Nature Biotechnology study combines large-scale experimental mapping with deep learning to predict and design cell-surface-display elements for mRNA-encoded antigens. The researchers quantified more than 570 chimeric antigens, assigned translocation-strength labels to approximately…
Shattuck Labs reported Phase 1 healthy-volunteer results for SL-325, a monoclonal antibody that blocks the TL1A receptor DR3. The company observed 3.7% anti-drug-antibody incidence and complete blockade of TL1A binding to DR3 for more…
Vaderis Therapeutics closed an oversubscribed $152 million Series B and announced initiation of the global Phase 3 HEROIC study of engasertib in moderate-to-severe hereditary hemorrhagic telangiectasia (HHT). The financing is expected to support planned…
